Abstract
Introduction
Early detection represents one of the most promising approaches to reducing the growing cancer burden [1] . The [2] . Over the past few years, evidence of circulating autoantibodies in the sera of cancer patients has created opportunities for exploiting the immune system as a source of cancer biomarkers. Indeed, the release of proteins from tumours triggers an immune response in cancer patients [3] . Considerable 
Unknown origins of autoantibody production in cancer
In the 1960s, Robert W. Baldwin demonstrated that the immune system could react to a developing tumour [4] [5] [6] [7] . However, these mechanisms are too often not effective enough to provide sufficient clinical responses [7] . Moreover, how exactly these natural autoantibodies originate remains a mystery [8] . One explanation is that they are secreted from self-reacting B cells that escape deletion [9] or from immature B cells [10] . [11] . Moreover, this amplification begins at an early stage when the tumour is not clinically detectable [12] .
Although little is known about the origin of this immune response, it is now largely established that cancer patients produce autoantibodies to mutated tumour proteins [13] , misfolded [14] , overexpressed [15] , aberrantly degraded [16] or aberrantly glycosylated proteins [17, 18] , and proteins that are ectopically expressed [11] . These spontaneous responses are frequently found in cancer patients, ranging from 5% to 30% for a single TAA. Therefore, because secreted autoantibodies reflect the presence of a tumoural burden, they represent attractive and suitable biomarkers for cancer detection.
The use of proteomics to identify autoantibodies
The technical difficulties in defining human autoantibody signatures related to the development of tumours, mainly based on the difficult establishment and limited availability of pre-characterized tumours cell cytotoxic T lymphocyte clones for most neoplasms [19] [25, 26] . This original natural protein microarray-based approach resulted in the identification of autoantibodies directed against C-terminal hydrolase L3 ubiquitin in the sera of patients with colon cancer [27] and autoantibodies directed against PGP9.5 in lung cancer [25] . Finally [29] . Reverse capture microarrays (Fig. 3 [22, 23] [39] [40] [41] [42] . There is a need for validation in an independent population that was used for the screening set. We can see in Table 1 that only several studies out of 13 [43, 44] [55] . These signatures also show that it is quite difficult to discriminate low grades from high grades [51] and lung cancer subtypes [45, 51] [56, 57] . Moreover, mammographic breast density appears to be a major risk factor for interval cancer [58, 59] [62 ,63, 65] [68] .
Fig. 2 Screening TAAs expressed in tumours or cell culture using SERPA. A complex mixture of proteins extracted from tumour or cell cultures is first separated by two-dimensional electrophoresis, according to their isoelectric points (pI; first dimension) and their molecular weights (second dimension; steps 1 and 2). Proteins are then transferred and immobilized on a membrane (step 3). Sera from cancer patients and controls are screened individually (step 4), allowing immunodetection of relevant antigens among the several thousand individual proteins separated using 2-DE. Comparative probing of blots allows selection of spots specifically reacting with cancer sera (step 5). These spots are then excised from the gel, and the proteins are identified by mass spectrometry (step 6). SERPA allows identification of protein isoforms and PTMs, but it has limitations in its identification

